Becton, Dickinson Invests in New Reagent Technology
Sirigen’s Brilliant Violet fluorophores are sold by BD, BioLegend and iCyt Mission. According to Oxford Capital, BD has had a six-year relationship with Sirigen. Sirigen’s High Sensitivity Fluorescence technology, which is based on chains of light-emitting polymers, can be designed for specific applications and detection platforms as well as integrated into existing assays.
Franklin Lakes, NJ 8/27/12; Oxford, UK 8/29/12—BD (Becton, Dickinson and Company) has purchased Sirigen Group, a developer of polymer dyes for flow cytometry and other technologies, for an undisclosed amount. BD stated that the company’s technology has the potential to create novel dyes that are four to ten times brighter than conventional dyes. “We believe that the acquisition will enable us to develop a continuous cadence of novel, unique dyes and antibody specificity releases over the next two years, significantly expanding our life science research reagent portfolio with high-impact products,” commented BD Biosciences President Alberto Mas. Sirigen has 15 employees. The transaction is expected to be dilutive to fiscal 2012 EPS by $0.01 on a GAAP basis.
